Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Lilly's obesity triple threat tops phase 3 efficacy forecasts
Lilly linked its triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee osteoarthritis.
Nick Paul Taylor
Dec 11, 2025 8:15am
Vanda tackles Wegovy-driven vomiting, sparking race to ph. 3
Nov 18, 2025 10:44am
Pfizer finalizes Metsera buy after contentious Novo bidding war
Nov 13, 2025 12:43pm
Zealand pumps brakes on development of dual GLP-1/GLP-2 agonist
Nov 13, 2025 9:52am
Novo CEO tells Pfizer to 'bid higher' if it wants to win Metsera
Nov 7, 2025 10:00am
Lilly links amylin drug to 20% weight loss, races to phase 3
Nov 6, 2025 8:20am
